Curadigm, an early-stage nanotechnology company dedicated to improving treatment outcomes by shifting the therapeutic delivery paradigm, today announced the selection of its project for the Sanofi iTech Awards program with its proprietary Nanoprimer technology. The Sanofi iTech Awards program aims to identify external innovations with the potential to significantly improve drug discovery and design, drug delivery and drug development within Sanofi. […]
The broad utility of the Nanoprimer technology is due to its unique nanomedicine approach to improve therapeutic action without modifying the therapeutic in any way. Rather, the Nanoprimer is administered intravenously just prior to a therapeutic, specifically and transiently occupying the liver pathways responsible for clearance. This temporarily increases the therapeutic’s bioavailability and subsequent accumulation in target tissue. […]